|Articles|September 17, 2020
Nitrosamine Testing: The Regulatory Aspects
Author(s)SGS
Detection of N-Nitrosodimethylamine (NDMA) impurities has led to regulatory warnings and product recalls. Pharmaceutical manufacturers must adopt a proactive approach to risk assessment and mitigation in relation to genotoxic contaminants.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Trending on Pharmaceutical Technology
1
Everything to Know About Pharmaceutical Tariffs in 2025
2
Behind the Headlines Episode 28: Navigating FDA Shakeups and Obesity Drug Wars
3
Challenges for the Global Manufacturing of Vaccines
4
Building Resilience in Pharma: Our Top 10 Questions from CPHI Frankfurt
5
